BioCryst Pharmaceuticals (STU:BO1) Total Liabilities : €922.9 Mil (As of Dec. 2024)

View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Total Liabilities?

BioCryst Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 was €922.9 Mil.

BioCryst Pharmaceuticals's quarterly Total Liabilities declined from Jun. 2024 (€880.72 Mil) to Sep. 2024 (€864.80 Mil) but then increased from Sep. 2024 (€864.80 Mil) to Dec. 2024 (€922.87 Mil).

BioCryst Pharmaceuticals's annual Total Liabilities increased from Dec. 2022 (€797.30 Mil) to Dec. 2023 (€891.77 Mil) and increased from Dec. 2023 (€891.77 Mil) to Dec. 2024 (€922.87 Mil).

BioCryst Pharmaceuticals Total Liabilities Historical Data

The historical data trend for BioCryst Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Total Liabilities Chart

BioCryst Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

290.97

615.20

797.30

891.77

922.87

BioCryst Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															891.77	868.53	880.72	864.80	922.87

BioCryst Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BioCryst Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	153.167	+	(769.701	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	922.9

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	468.351	-	-454.517
	=	922.9

BioCryst Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	153.167	+	(769.701	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	922.9

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	468.351	-	-454.517
	=	922.9

BioCryst Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCryst Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (STU:BO1) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BCRX:USA BO1:Germany

Address

4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703

Website

https://www.biocryst.com

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BioCryst Pharmaceuticals Headlines

No Headlines